XenoPort to Release Third Quarter Financial Results on November 3, 2009
More News related to XNPT
- XenoPort (XNPT) and Astellas Pharma Announce an Application for RLS Treatment XP13512 Filed with PMDA in Japan
- Astellas and XenoPort Announce Submission of a New Drug Application in Japan Requesting PMDA Approval of ASP8825/XP13512 for Restless Legs Syndrome
- CORRECTING and REPLACING GlaxoSmithKline and XenoPort Announce Extension of GSK1838262 (XP13512) FDA Review Date to February 9, 2010
- Glaxo (GSK) and XenoPort (XNPT) Announed that U.S. FDA Has Extended the Review Date of GSK1838262/XP13512
- GlaxoSmithKline and XenoPort Announce Extension of GSK1838262 (XP13512) FDA Review Date to February 9, 2010
More News related to Press Releases
- Interesting Call Buying In Research In Motion (RIMM)
- Broadpoint.AmTech Reiterates a 'Buy' on Marvell Technology (MRVL); Raises Estimates & PT
- Unemployment Data Brings Hope: Art Hogan Weighs In
- Brean Murray Maintains a 'Buy' on athenahealth (ATHN); Lofty Valuation Surpassed Only by Lofty Goals
- Benchmark Raises American Tower's (AMT) Price Target to $50 on Strong Tower Demand
SANTA CLARA, Calif.--(BUSINESS WIRE)-- XenoPort, Inc. (Nasdaq: XNPT) announced today that it will release its third quarter financial results on November 3, 2009 at approximately 4:00 p.m. Eastern Time. The company will host a conference call at 4:30 p.m. Eastern Time that same day. A replay of the call will be available for one week following the event.
To access the conference call via the Internet, go to www.XenoPort.com. Please join the call at least 15 minutes prior to the start to ensure time for any software downloads that may be required.
To access the live conference call via phone, dial 1-888-275-3514. International callers may access the live call by dialing 706-679-1417. The reference number to enter the call is 38475337.
The replay of the conference call may be accessed that same day after 8:00 p.m. Eastern Time, via the Internet, at www.XenoPort.com, or via phone at 1-800-642-1687 for domestic callers, or 706-645-9291 for international callers. The reference number to enter the replay of the call is 38475337.
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. XenoPort is developing its lead product candidate, XP13512, in collaboration with Astellas Pharma Inc. and GlaxoSmithKline (GSK). The Food and Drug Administration is currently reviewing GSK's NDA for XP13512 as a potential treatment for moderate-to-severe primary restless legs syndrome in the United States. XenoPort's product candidates are also being studied for the potential treatment of restless legs syndrome, gastroesophageal reflux disease, migraine headaches, neuropathic pain, spasticity and Parkinson's disease.
To learn more about XenoPort, please visit the Web site at www.XenoPort.com.
XenoPort is a registered trademark of XenoPort, Inc.
XNPT2F
Source: XenoPort, Inc.
Related Categories
Press ReleasesStocks Mentioned
+0.10Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
